Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study
Hizal, M.; Bilgin, B.; Paksoy, N.; Klllçkap, S.; Atcl, M.M.; Kahraman, S.; Keskinklllç, M.; Bilgetekin, Ä.; Ayhan, M.; Tural, D.; Eren, O.; Mustafayev, F.N.A.; Yaman, S.; Tatll, A.M.; Bayram, E.; Kutlu, Y.; Ertürk, I.; Özcan, E.; Gülmez, A.; Korkmaz, M.; Akagündüz, B.; Erdem, D.; Telli, T.A.; Aksoy, A.; Üskent, N.; Iriagac, Y.; Baytemür, N.K.; Aydln, D.; Å akalar, T.; Arak, H.; Selçukbiricik, F.; Ergün, Y.; Korkmaz, T.; Ak, N.; Ünal, C.; Akdeniz, N.; Özgün, M.A.; Öksüzoglu, B.; Yalçln, B.; Öztop, I.; Algln, E.; Sakin, A.; Aydlner, A.; Yumuk, P.F.; Sendur, M.A.N.
Tarih:
2022
Özet:
Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. Results & conclusion: A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile. © 2022 Future Medicine Ltd.
Tüm öğe kaydını göster